title: Anti-inflammatory effect of fullerene C60 in a mice model of atopic dermatitis.
abstract: BACKGROUND
  Water-soluble form of fullerene C60 is a promising tool for the control of ROS-dependent inflammation including allergic diseases. Anti-inflammatory effects of C60 (nC60) aqueous dispersion were evaluated in the mouse models of atopic dermatitis using subcutaneous (SC) and epicutaneous (EC) applications during 50 days period. A highly stable nC60 was prepared by exhaustive dialysis of water-organic C60 solution against water, where the size and ζ-potential of fullerene nanoparticles are about 100 nm and -30 mV, respectively.
  
  
  RESULTS
  To induce skin inflammation, female BALB/c mice were EC sensitized with ovalbumin three times during one-weekly exposures. The nC60 solution was administrated in mice subcutaneously (SC) (0.1 mg/kg) and epicutaneously (EC) (1 mg/kg). Significant suppression of IgE and Th2 cytokines production and a concomitant rise in concentrations of Th1 cytokines were observed in nC60-treated groups. In addition, a significant increase in the levels of Foxp3(+) and filaggrin mRNA expression was observed at EC application. Histological examination of skin samples indicated that therapeutic effect was achieved by both EC and SC treatment, but it was more effective with EC. Pronounced reduction of the eosinophil and leukocyte infiltration in treated skin samples was observed.
  
  
  CONCLUSIONS
  We suppose that nC60 treatment shifts immune response from Th2 to Th1 and restores to some extent the function of the skin barrier. This approach can be a good alternative to the treatment of allergic and other inflammatory diseases.
authors.affiliation: NRC Institute of Immunology FMBA of Russia, Moscow, Russia. nn.shershakova@nrcii.ru.
authors.forename: Nadezda
authors.initials: N
authors.lastname: Shershakova
authors.affiliation: NRC Institute of Immunology FMBA of Russia, Moscow, Russia. en.bashkatova@nrcii.ru.
authors.forename: Elena
authors.initials: E
authors.lastname: Baraboshkina
authors.affiliation: NRC Institute of Immunology FMBA of Russia, Moscow, Russia. sm.andreev@nrcii.ru.
authors.forename: Sergey
authors.initials: S
authors.lastname: Andreev
authors.affiliation: NRC Institute of Immunology FMBA of Russia, Moscow, Russia. dd.purgina@nrcii.ru.
authors.forename: Daria
authors.initials: D
authors.lastname: Purgina
authors.affiliation: NRC Institute of Immunology FMBA of Russia, Moscow, Russia. ira9ctpy4@rambler.ru.
authors.forename: Irina
authors.initials: I
authors.lastname: Struchkova
authors.affiliation: NRC Institute of Immunology FMBA of Russia, Moscow, Russia. oy.kamyshnikov@nrcii.ru.
authors.forename: Oleg
authors.initials: O
authors.lastname: Kamyshnikov
authors.affiliation: NRC Institute of Immunology FMBA of Russia, Moscow, Russia. aa.nikonova@nrcii.ru.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Nikonova
authors.affiliation: NRC Institute of Immunology FMBA of Russia, Moscow, Russia. mr.khaitov@nrcii.ru.
authors.forename: Musa
authors.initials: M
authors.lastname: Khaitov
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D016207:Cytokines / Q000378:metabolism; D003876:Dermatitis, Atopic / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D000091344:Filaggrin Proteins; D051858:Forkhead Transcription Factors / Q000378:metabolism; D037741:Fullerenes / Q000494:pharmacology*; D007073:Immunoglobulin E / Q000378:metabolism; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D007381:Intermediate Filament Proteins / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D012867:Skin / Q000187:drug effects / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; D016207:Cytokines; D000091344:Filaggrin Proteins; D051858:Forkhead Transcription Factors; D037741:Fullerenes; D007381:Intermediate Filament Proteins; D012333:RNA, Messenger; D007073:Immunoglobulin E; D010047:Ovalbumin; C069837:fullerene C60
references.citation: Environ Sci Technol. 2012 Mar 20;46(6):3457-64
references.pmid: 22352688
references.citation: J Clin Invest. 1998 Apr 15;101(8):1614-22
references.pmid: 9541491
references.citation: Nanotechnology. 2008 Apr 9;19(14):145102
references.pmid: 21817752
references.citation: Cytokine. 2015 Oct;75(2):249-55
references.pmid: 25796985
references.citation: Int J Nanomedicine. 2014;9:5143-56
references.pmid: 25395851
references.citation: J Dermatol Sci. 2012 Oct;68(1):3-8
references.pmid: 22771322
references.citation: J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1405-8
references.pmid: 20205355
references.citation: J Allergy Clin Immunol. 2014 Jan;133(1):139-46.e1-10
references.pmid: 24055295
references.citation: Nature. 2006 Aug 31;442(7106):997-1002
references.pmid: 16921386
references.citation: Curr Drug Targets Inflamm Allergy. 2005 Aug;4(4):517-9
references.pmid: 16127829
references.citation: Biomaterials. 2012 Jun;33(19):4936-46
references.pmid: 22498298
references.citation: J Immunol. 2007 Jul 1;179(1):665-72
references.pmid: 17579089
references.citation: Allergy. 2013 Apr;68(4):498-506
references.pmid: 23452057
references.citation: Dokl Biochem. 2000 Jan-Feb;370(1-6):4-7
references.pmid: 11977250
references.citation: Parasite Immunol. 1994 Oct;16(10):521-7
references.pmid: 7870462
references.citation: Br J Dermatol. 2003 Aug;149(2):248-54
references.pmid: 12932228
references.citation: Nano Lett. 2005 Dec;5(12):2578-85
references.pmid: 16351219
references.citation: Annu Rev Immunol. 2001;19:683-765
references.pmid: 11244051
references.citation: PLoS One. 2015;10(8):e0135070
references.pmid: 26275152
references.citation: Int J Nanomedicine. 2011;6:2459-67
references.pmid: 22072881
references.citation: Adv Exp Med Biol. 2015;849:1-10
references.pmid: 25510360
references.citation: J Allergy Clin Immunol. 2006 Jan;117(1):176-83
references.pmid: 16387603
references.citation: Curr Allergy Asthma Rep. 2009 Jul;9(4):291-4
references.pmid: 19656476
references.citation: N Engl J Med. 2008 Apr 3;358(14):1483-94
references.pmid: 18385500
references.citation: Int J Dermatol. 2011 Mar;50(3):247-54
references.pmid: 21342155
references.citation: Clin Transl Sci. 2010 Aug;3(4):158-69
references.pmid: 20718816
references.citation: Front Biosci (Landmark Ed). 2014;19:542-56
references.pmid: 24389202
references.citation: Curr Opin Allergy Clin Immunol. 2007 Oct;7(5):382-6
references.pmid: 17873576
references.citation: Int J Immunopathol Pharmacol. 2010 Jan-Mar;23(1):131-41
references.pmid: 20378001
references.citation: Toxicology. 2009 Jun 30;261(1-2):19-24
references.pmid: 19376187
references.citation: Allergy. 2014 Dec;69(12):1571-81
references.pmid: 25283085
references.citation: Nat Genet. 2006 Apr;38(4):441-6
references.pmid: 16550169
references.citation: Res Vet Sci. 2012 Jun;92(3):469-70
references.pmid: 21601227
references.citation: J Allergy Clin Immunol. 2004 Apr;113(4):756-63
references.pmid: 15100684
references.citation: Int J Nanomedicine. 2012;7:4571-80
references.pmid: 22942641
references.citation: Ann Dermatol. 2010 May;22(2):125-37
references.pmid: 20548901
references.citation: ACS Nano. 2012 Aug 28;6(8):6829-42
references.pmid: 22797484
references.citation: Exp Dermatol. 2009 Dec;18(12):1079-81
references.pmid: 19555428
references.citation: Redox Rep. 2013;18(3):88-94
references.pmid: 23601165
references.citation: J Nanobiotechnology. 2015;13:50
references.pmid: 26253116
references.citation: J Allergy Clin Immunol. 2003 Apr;111(4):875-81
references.pmid: 12704372
references.citation: J Allergy Clin Immunol Pract. 2013 Mar;1(2):142-51
references.pmid: 24565453
references.citation: Part Fibre Toxicol. 2014;11:38
references.pmid: 25123235